SYK and lymphoma: The identification of SYK as a master regulator of anti-apoptotic signaling in B-lineage leukemia/lymphoma cells prompted the development of SYK inhibitors as a new class of anti-cancer drug candidates (Uckun and Qazi, 2010, D'Cruz and Uckun, 2012, Myers et al., 2014, Uckun et al., 2013, Perova et al., 2014, Wang et al., 2014, Geahlen, 2014).